1. Home
  2. SKYE vs DSP Comparison

SKYE vs DSP Comparison

Compare SKYE & DSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

HOLD

Current Price

$0.83

Market Cap

44.9M

Sector

Health Care

ML Signal

HOLD

Logo Viant Technology Inc.

DSP

Viant Technology Inc.

HOLD

Current Price

$11.93

Market Cap

198.1M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
SKYE
DSP
Founded
2012
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
44.9M
198.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
SKYE
DSP
Price
$0.83
$11.93
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
8
Target Price
$14.75
$18.50
AVG Volume (30 Days)
350.9K
247.4K
Earning Date
11-10-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
29.49
EPS
N/A
0.10
Revenue
N/A
$324,131,000.00
Revenue This Year
N/A
$17.79
Revenue Next Year
N/A
$17.72
P/E Ratio
N/A
$120.74
Revenue Growth
N/A
22.97
52 Week Low
$0.82
$8.11
52 Week High
$5.75
$26.33

Technical Indicators

Market Signals
Indicator
SKYE
DSP
Relative Strength Index (RSI) 28.16 63.17
Support Level $0.82 $11.54
Resistance Level $0.95 $12.15
Average True Range (ATR) 0.11 0.50
MACD -0.01 -0.04
Stochastic Oscillator 8.77 61.13

Price Performance

Historical Comparison
SKYE
DSP

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About DSP Viant Technology Inc.

Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. It operates a cloud-based demand side platform ("DSP") that is used by marketers and its advertising agencies to centralize the planning, buying and measurement of its advertising across channels, including connected TV (CTV), streaming audio, digital out-of-home, mobile and desktop.

Share on Social Networks: